Dr. Reddy’s outlines semaglutide relaunch in November 2026 and reiterates 6M-7M devices target (NYSE:RDY)
· seekingalpha.com
Dr. Reddy’s Q2 FY27 earnings call: margin recovery, semaglutide relaunch timing, and biosimilar catalysts.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...